Prediction markets / Technology / Science

Will the FDA approve any psychedelic substance for medical use before 2027?

Before 202753¢
LIVE
1D
1W
MAX

Select a contract

Timeline

Trading hours
24 hours a day, except Thursday 3AM-5AM ET
Contract resolves
Determines the outcome of the contract
Payout
Usually within 1 hour of event resolution

About

Will the FDA approve any psychedelic substance for medical use before 2027? Outcome verified from FDA and U.S. Food and Drug Administration. Psychedelic drugs include: LSD, Psilocybin, DMT, Mescaline, MDMA, MDA,, PCP, DXM, Ibogaine, Salvia divinorum, 2C family, and Ayahuasca.Important information: For purposes of this Contract:The listed substances are illustrative, not exhaustive. Approval of any other substance commonly recognized in scientific or FDA documentation as a psychedelic, hallucinogen, or entactogen (for example, psilocin, 5-MeO-DMT, methylone, or 2C-, DOx-, or NBOMe-family compounds) may also satisfy the Payout Criterion."Approval for medical use" means an FDA approval letter for an NDA or BLA authorizing marketing of a drug or biologic for human medical use in the United States, where a listed (or otherwise qualifying) psychedelic substance is an active pharmaceutical ingredient of the approved product. Complete Response Letters, tentative approvals, Emergency Use Authorizations, expanded access or compassionate use authorizations, and approvals limited to export do not satisfy the Payout Criterion.Combination products. Approval of a combination drug product satisfies the Payout Criterion only if at least one active ingredient is a listed (or otherwise qualifying) psychedelic substance and that psychedelic active ingredient has not previously been approved by the FDA via NDA or BLA for any human medical indication. By way of example, an FDA approval of AXS-05 (a combination of dextromethorphan and bupropion) for a new indication does not satisfy the Payout Criterion, because both active ingredients were FDA-approved prior to Issuance.New indications for previously-approved substances. An FDA approval (including via supplemental NDA or supplemental BLA) of a new medical indication, dosage, or formulation for a substance whose active pharmaceutical ingredient was already approved by the FDA via NDA or BLA prior to Issuance does not satisfy the Payout Criterion.Advisory Committee votes, sponsor withdrawals, and CRLs do not by themselves resolve the Contract. Resolution turns solely on whether a qualifying FDA approval letter is issued after Issuance and before January 1, 2027.Get $1 for every contract you own if your prediction is correct. Or close your position before the event resolves. Additional fees apply. Read the full contract terms and conditions

Trading prohibitions

  • Persons who are employed by any of the Source Agencies are not permitted to trade on the Contract.
  • Persons who hold any material, non-public information on the Underlying are not permitted to trade on the Contract.

Similar events

How many launches will SpaceX have in May
Will the U.S. confirm that aliens exist before 2027?
Will Elon win his case against OpenAI?
How many launches will SpaceX have in 2026
Best AI at the end of 2026?
US grants license for new nuclear reactor before 2027?
Best AI this week
Price of NVIDIA H100 SXM compute by May 31, 2026
Restrictions and eligibility requirements apply. Futures, options on futures and cleared swaps trading involves significant risk and is not appropriate for everyone. Please carefully consider if it is appropriate for you in light of your personal financial circumstances.
Read the Event Contracts Risk Disclosure for more information about the risks associated with event contracts.
Live data is for informational purposes only. It maybe delayed or incorrect.
Event contracts are offered by Robinhood Derivatives, LLC through either KalshiEX LLC or ForecastEX, LLC.